Antroquinonol for Metastatic Pancreatic Cancer as First-Line Treatment

Model: Antroquinonol for Pancreatic Cancer

Booth No: M316

Characteristic

Golden Biotech's lead compound, Antroquinonol, is a novel small molecule targeting key oncogenic and immunological pathways, currently in development for multiple oncology indications. In metastatic pancreatic cancer, Antroquinonol—administered orally—has shown compelling results when combined with the standard of care (nab-paclitaxel plus gemcitabine), demonstrating an extended median overall survival (mOS) in a Phase II clinical trial as a first-line treatment. Antroquinonol’s excellent safety profile is distinguished by a significant reduction in hematologic adverse events, such as neutropenia, thrombocytopenia, anemia, and leukopenia, compared to standard treatments, as well as lower rates of non-hematologic side effects like fatigue and neuropathy. Its oral formulation, low potential for drug-drug interactions, and robust safety data make it an attractive candidate for both combination and standalone use.

Mechanistically, Antroquinonol inhibits the PI3K/Akt/mTOR pathway and disrupts cell cycle progression, inducing apoptosis, autophagy, and senescence in pancreatic cancer cells—particularly relevant for the high prevalence of KRAS mutations in this disease. The compound has received Orphan Drug Designation from the FDA for pancreatic cancer, AML, and hepatocellular carcinoma, and from the EMA for pancreatic cancer, underscoring its therapeutic promise.

Golden Biotech presents Antroquinonol, a novel small molecule, which exhibits significant anti-cancer activities through selected mechanisms targeting cancer cell growth, survival and metastasis. Antroquinonol has completed Phase 2 clinical studies in Metastatic Pancreatic cancer, Non-small Cell Lung cancer and Acute Myeloid Leukemia.

A Global Phase 3 Study is currently in development with Antroquinonol as First Line treatment in Metastatic Pancreatic Cancer. To showcase the clinical potential of Antroquinonol in metastatic pancreatic cancer and to engage with potential partners for our upcoming multi-center, multi-country Phase 3 trial, we aim to explore strategic collaborations in clinical development, licensing, and global commercialization.